Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 4—April 2018
Research

Avirulent Bacillus anthracis Strain with Molecular Assay Targets as Surrogate for Irradiation-Inactivated Virulent Spores

Roger D. Plaut, Andrea B. Staab, Mark A. Munson, Joan S. Gebhardt, Christopher P. Klimko, Avery V. Quirk, Christopher K. Cote, Tony L. Buhr, Rebecca D. Rossmaier, Robert C. Bernhards, Courtney E. Love, Kimberly L. Berk, Teresa G. Abshire, David A. Rozak, Linda C. Beck, Scott Stibitz, Bruce G. Goodwin, Michael A. Smith, and Shanmuga SozhamannanComments to Author 
Author affiliations: Food and Drug Administration, Silver Spring, Maryland, USA (R.D. Plaut, S. Stibitz); Naval Surface Warfare Center, Dahlgren, Virginia, USA (A.B. Staab, T.L. Buhr, L.C. Beck); Naval Medical Research Center, Fort Detrick, Maryland, USA (M.A. Munson, J.S. Gebhardt); US Army Medical Research Institute of Infectious Diseases, Fort Detrick (C.P. Klimko, A.V. Quirk, C.K. Cote, T.G. Abshire, D.A. Rozak); US Army Edgewood Chemical and Biological Center, Aberdeen Proving Ground, Maryland, USA (R.D. Rossmaier, R.C. Bernhards, C.E. Love, K.L. Berk); Defense Threat Reduction Agency, Fort Belvoir, Virginia, USA (R.C. Bernhards); Joint Research and Development, Inc., Stafford, Virginia, USA (C.E. Love, L.C. Beck); Defense Biological Product Assurance Office, Frederick, Maryland, USA (B.G. Goodwin, M.A. Smith, S. Sozhamannan); The Tauri Group, Inc., Alexandria, Virginia, USA (S. Sozhamannan)

Main Article

Table 2

Description of the DNA inserts in the recombinant Bacillus anthracis surrogate strain*

Replicon of assay target WT gene Size, bp Assay WT insert size, bp (%)† Mutant insert size, bp‡ Predicted biological characteristic of recombinant product Antimicrobial resistance/sensitivity of recombinant product
pXO2 capA 1,236 Signature 1 98 (7.9) 98 NC (Tox−Cap−) SpcS, KanS, AmpS
pXO1 pagA 2,295 Signature 2 110 (4.8) 113 NC (Tox−Cap−) SpcS, KanS, AmpS
pXO1 pagA 2,295 Signature 3 137 (6.0) 142 NC (Tox−Cap−) SpcS, KanS, AmpS
pXO2 capB 1,395 Signature 4 182 (13.0) 186 NC (Tox−Cap−) SpcS, KanS, AmpS
pXO1 pagA 2,295 Signature 5 153 (6.67) NA NC (Tox−Cap−) SpcS, KanS, AmpS
Bar code 1 NS 78 NA NA NA NA NA
Bar code 2 NS 90 NA NA NA NA NA

*Amp, ampicillin; Cap–, capsule negative; Kan, kanamycin; NA, not applicable; NC, no change from parent; NS, nonbiological, nonprotein-coding sequence; S, sensitive; Tox–, protective antigen (PA), lethal factor (LF), and edema factor (EF) negative; Spc, spectinomycin; WT, wild-type.
†Percentage of the wild-type gene.
‡Contain unique restriction sites.

Main Article

Page created: March 19, 2018
Page updated: March 19, 2018
Page reviewed: March 19, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external